Treatment of chronic hepatitis C in Europe

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 10, Issue 2, 2003, Pages 168-171

  Colombo, Massimo ^a   Rumi, Maria Grazia ^a   Del Ninno, Ersilio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic hepatitis C; Combination therapy; Interferon; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

AGE; ARTICLE; BODY WEIGHT; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG INDICATION; DRUG RESPONSE; DYSPNEA; EUROPE; FEMALE; GENDER; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PATIENT COMPLIANCE; PREDICTION; PRURITUS; RASH; RISK ASSESSMENT; VIREMIA;

DRUG THERAPY, COMBINATION; EUROPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0141702081     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-002-0728-4     Document Type: Article

References (14)

1. Colombo M (1999) Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 31(Suppl 1):25-30
2. Lindsay KL (1997) Therapy of hepatitis C: overview. Hepatology 26:71S-77S
3. Davis GL, Lau JYN (1997) Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26:122S-127S
4. Weiland O (1999) Treatment of naive patients with chronic hepatitis C. J Hepatol 31(Suppl 1):168-173
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk G, Ideo G, Bain V, Heatcote J, Zeuze, S, Trepo C, Albrecht J, for the International Hepatitis Interventional Therapy Group (IHIT) (1998) Randomised trial of interferon α26 plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432
6. Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoofman J, Brunda MJ (2000) Peginteferon alfa-2a in patients with chronic hepatitis. N Engl J Med 343:1666-1672
7. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, and the International Hepatitis Interventional Therapy Group (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965
8. Poynard T, McHutchinson JG, Goodman Z, Ling MH, Albrecht J, ALGOVIRC project group (2000) Is an "a la carte" combination interferon alpha 2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31:211-218
9. Foster GR (1999) Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 31(Suppl 1):250-254
10. Saracco G, Ciangio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, Cariti G, Andreoni M, Biglino A, Calleri G, Maggi G, Tappero GF, Orsi PG, Terreni N, Macor A, Di Napoli A, Rinaldi E, Ciccone G, Rizzetto M for the North Western Italian Hepatology Group (2001) A randomized four- arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C non-responding to interferon alone. Hepatology 34:133-138
11. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, for the German Acute Hepatitis C Therapy Group (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1542-1457
12. Tassopoulos NC (1999) Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 31(Suppl 1):193-196
13. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680
14. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrect JK, for the Hepatitis Interventional Therapy Group (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403